Aclaris Therapeutics, Inc. (ACRS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions.
Analysis Summary
Aclaris Therapeutics, Inc. reported revenue of $7.8M in the most recent fiscal year, growing at a 5-year CAGR of 3.8%.
Trailing-twelve-month margins: gross margin 95.6%, operating margin -10.5%, net margin -9.2%.
At the current price of $5.32, ACRS has negative trailing earnings (P/E not meaningful) and an ROE of -61.65%. Market capitalisation stands at $743M.
Balance sheet quality for ACRS: current ratio of 5.3, net cash position of $88.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $5.32 |
| Market Cap | $743M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.25 |
| EV / EBITDA | -11.22 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -61.65% |
| Return on Invested Capital | -56.99% |
| Return on Assets | -42.15% |
| Gross Margin | 95.61% |
| Operating Margin | -1050.16% |
| Net Margin | -921.50% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.46 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -5.19 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $743M | 6.25 | -61.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -15.69% |
| 3 months | +18.22% |
| Year-to-date | +76.74% |
| 1 year | +193.92% |
| 3 years | -28.40% |
| 5 years | -70.70% |
52-Week Range
| 52-week High | $6.60 |
| 52-week Low | $1.74 |
| Avg Volume (90d) | 1.9M |
Related companies: ALLO · BIOA · CABA · EDIT · MASS · MDXH · NEO
Explore sector: Healthcare · Biotechnology
More sections of ACRS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks